Dupilumab for Chronic Prurigo in Different Backgrounds: A Case Series

Chronic prurigo (CPG) is a chronic inflammatory disease characterized by intense pruritus, and therapy is often challenging due to its unclear pathogenesis. Here, we report four patients with refractory CPG from different backgrounds who experienced failure of conventional therapy and were controlle...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Nana, Wang, Qiuyue, Lei, Min, Li, Tianhao, Hao, Pingsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480179/
https://www.ncbi.nlm.nih.gov/pubmed/36117770
http://dx.doi.org/10.2147/CCID.S379231
_version_ 1784790992526770176
author Luo, Nana
Wang, Qiuyue
Lei, Min
Li, Tianhao
Hao, Pingsheng
author_facet Luo, Nana
Wang, Qiuyue
Lei, Min
Li, Tianhao
Hao, Pingsheng
author_sort Luo, Nana
collection PubMed
description Chronic prurigo (CPG) is a chronic inflammatory disease characterized by intense pruritus, and therapy is often challenging due to its unclear pathogenesis. Here, we report four patients with refractory CPG from different backgrounds who experienced failure of conventional therapy and were controlled with dupilumab, accompanied by a significant decrease in pruritus numerical rating scale, dermatology life quality index, and investigator global assessment, without adverse effects. Furthermore, dupilumab improved the condition of asthma in CPG patients along with an increase in asthma control test scores.
format Online
Article
Text
id pubmed-9480179
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-94801792022-09-17 Dupilumab for Chronic Prurigo in Different Backgrounds: A Case Series Luo, Nana Wang, Qiuyue Lei, Min Li, Tianhao Hao, Pingsheng Clin Cosmet Investig Dermatol Case Series Chronic prurigo (CPG) is a chronic inflammatory disease characterized by intense pruritus, and therapy is often challenging due to its unclear pathogenesis. Here, we report four patients with refractory CPG from different backgrounds who experienced failure of conventional therapy and were controlled with dupilumab, accompanied by a significant decrease in pruritus numerical rating scale, dermatology life quality index, and investigator global assessment, without adverse effects. Furthermore, dupilumab improved the condition of asthma in CPG patients along with an increase in asthma control test scores. Dove 2022-09-12 /pmc/articles/PMC9480179/ /pubmed/36117770 http://dx.doi.org/10.2147/CCID.S379231 Text en © 2022 Luo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Series
Luo, Nana
Wang, Qiuyue
Lei, Min
Li, Tianhao
Hao, Pingsheng
Dupilumab for Chronic Prurigo in Different Backgrounds: A Case Series
title Dupilumab for Chronic Prurigo in Different Backgrounds: A Case Series
title_full Dupilumab for Chronic Prurigo in Different Backgrounds: A Case Series
title_fullStr Dupilumab for Chronic Prurigo in Different Backgrounds: A Case Series
title_full_unstemmed Dupilumab for Chronic Prurigo in Different Backgrounds: A Case Series
title_short Dupilumab for Chronic Prurigo in Different Backgrounds: A Case Series
title_sort dupilumab for chronic prurigo in different backgrounds: a case series
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480179/
https://www.ncbi.nlm.nih.gov/pubmed/36117770
http://dx.doi.org/10.2147/CCID.S379231
work_keys_str_mv AT luonana dupilumabforchronicprurigoindifferentbackgroundsacaseseries
AT wangqiuyue dupilumabforchronicprurigoindifferentbackgroundsacaseseries
AT leimin dupilumabforchronicprurigoindifferentbackgroundsacaseseries
AT litianhao dupilumabforchronicprurigoindifferentbackgroundsacaseseries
AT haopingsheng dupilumabforchronicprurigoindifferentbackgroundsacaseseries

Ejemplares similares